Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Mladsi DM, Barrett AM. Winners and losers: patterns in economic evaluations of anti-epileptic drugs. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A83.
Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A42.
Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).
Davis KL, Candrilli SD, Kan H, Lucero MA, Covington M. Estimating the effects of diabetic peripheral neuropathy and diabetic retinopathy on quality-of-life using data from the 2001-2002 national health and nutrition examination survey. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 18, 2005. [abstract] Value Health. 2005 May; 8(3):365.
Davis KL, Candrilli SD, Kan HJ, Lucero MA, Covington MT. Estimating the effect of symptoms of diabetic peripheral neuropathy and diabetic retinopathy on quality-of-life using data from the 2001-2002 national health and nutrition examination survey. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):365.
Candrilli SD, Davis KL, Kan H, Lucero MA, Covington M. Burden of illness associated with symptoms of diabetic peripheral neuropathy and diabetic retinopathy. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 18, 2005. [abstract] Value Health. 2005 May; 8(3):357.
von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).
Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.
von Scheele B, DePlatchett J, Gaffney L, Peña BM, Niculescu L. The total costs of treatment with valdecoxib compared to generic diclofenac are similar in patients with rheumatoid arthritis in Germany. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):725-6.
Beard S, Gaffney L, Bamber L. Economic modelling of antiplatelet therapy in the prevention of recurrent stroke. Value Health. 2003 Jan 1;6(6):650.
Earnshaw SR, Richter A, Hicks K, Honeycutt A. The allocation of HIV prevention funds. Value Health. 2003 Jan 1;6(3):254.
Neighbors D, Irish WD, Lopez R, Degen K, Swann A, Grogg A. Inpatient medication utilization and costs of risperidone, olanzapine, and quetiapine: a retrospective chart abstraction study. Poster presented at the 2002 ISPOR 7th Annual International Meeting; May 19, 2002. Arlington, VA. [abstract] Value Health. 2002 May; 5(3):234.
Mauskopf JA, Bell LN, Neighbors DM, Dombeck M. Estimating the return on investment for tuberculosis drugs. Poster presented at the 2001 ISPOR 4th Annual European Congress; November 11, 2001. Cannes, France. [abstract] Value Health. 2001 Sep; 4(6):446.
Dombeck M, Earnshaw SR, Candrilli SD, Xuan J, Bakst A, Kirsch JM. Modeling antibiotic efficacy by infectious agent and probability of resistance. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress; November 2001. [abstract] Value Health. 2001 Sep; 4(6):427.
Alexeyeva I, Mauskopf JA, Earnshaw SR, Gibson JP, Ascher-Svanum H, Ramsey J. A model comparing olanzapine and ziprasidone in patients with schizophrenia. Poster presented at the 2001 ISPOR 6th Annual International Meeting; May 2001. [abstract] Value Health. 2001 Sep; 4(2):148-9.
Neighbors D, Buckingham T, Greiner W, Schulenburg J. Potential cost savings of the 4 French infiniti catheter in diagnostic coronary angiography. Poster presented at the Inaugural European Congress of the International Society for Pharmacoeconomics and Outcomes Research; December 1998. Cologne, Germany. [abstract] Value Health. 1999 Jan; 2(1):25. doi: 10.1016/S1098-3015(11)70103-6